Swarnima Pandey¹* and Sushant Kumar²

¹Department of Pharmacy, Hygia College of Pharmacy, Affiliated to Dr. APJ AKTU, Lucknow, India
²Department of Pharmacy, Uttar Pradesh University of Medical Sciences, Saifai, Etwah, India

*Corresponding Author: Swarnima Pandey, Department of Pharmacy, Hygia College of Pharmacy, Affiliated to Dr. APJ AKTU, Lucknow, India

Received: January 31, 2022; Published: February 24, 2022

Abstract

The development of osteoporosis begins when the bone becomes porous and weaker, due to which the risk of fractures increases, especially in the hips, spinal vertebrae, and some peripheral joints. In this review article, we have compiled the causes, risk factors, and various herbal plants which can be used for the treatment of osteoporosis.

Keywords: Osteoporosis; Bone Matrix; Herbal Plants

References

1. McCloskey E., et al. “FRAX-based assessment and intervention thresholds—an exploration of thresholds in women aged 50 years and older in the UK”. Osteoporosis International8 (2015): 2091-2099.
2. Chen P., et al. “Prevalence of osteoporosis in China: a meta-analysis and systematic review”. BMC Public Health1 (2016): 1039.
3. Jia M., et al. “Potential antiosteoporotic agents from plants: a comprehensive review”. Evidence-Based Complementary and Alternative Medicine 2012 (2012).
4. Cummings SR., et al. “Risk factors for hip fracture in white women”. New England Journal of Medicine12 (1995): 767-773.
5. Drake MT., et al. “Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis”. The Journal of Clinical Endocrinology and Metabolism6 (2012): 1861-1870.
6. Bone HG., et al. “Ten years' experience with alendronate for osteoporosis in postmenopausal women”. New England Journal of Medicine12 (2004): 1189-1199.
7. Sözen T., et al. “An overview and management of osteoporosis”. European Journal of Rheumatology1 (2017): 46.
8. Runowicz CD., et al. “American cancer society/American society of clinical oncology breast cancer survivorship care guideline”. CA: A Cancer Journal for Clinicians1 (2016): 43-73.
9. Lewiecki EM., et al. “Hip fracture trends in the United States, 2002 to 2015”. Osteoporosis International3 (2018): 717-722.
10. Eastell R. “Treatment of postmenopausal osteoporosis”. New England Journal of Medicine11 (1998): 736-746.
11. Kanis JA., et al. “The diagnosis of osteoporosis”. Journal of Bone and Mineral Research8 (1994): 1137-1141.
12. Brown JP and Josse RG. “2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada”. CMAJ 167 (2002): S1-S34.
13. Miller PD. “Underdiagnoses and undertreatment of osteoporosis: the battle to be won”. The Journal of Clinical Endocrinology and Metabolism3 (2016): 852-859.
14. Tabatabaei-Malazy O., et al. “New horizons in treatment of osteoporosis”. DARU Journal of Pharmaceutical Sciences1 (2017): 2.
15. Crockett JC., et al. “Bone remodelling at a glance”. Journal of Cell Science7 (2011): 991-998.
16. Raisz LG. “Pathogenesis of osteoporosis: concepts, conflicts, and prospects”. The Journal of Clinical Investigation12 (2005): 3318-3325.
17. Tuzun S., et al. “Incidence of hip fracture and prevalence of osteoporosis in Turkey: the FRACTURK study”. Osteoporosis International3 (2012): 949-955.
18. Nuti R., et al. “Guidelines for the management of osteoporosis and fragility fractures”. Internal and Emergency Medicine1 (2019): 85-102.
19. Nancy J. “A study to assess the effectiveness of structured teaching programme on knowledge regarding prevention of osteoporosis among health care personnel working in Rajiv Gandhi Government General Hospital, Chennai: College of Nursing, Madras Medical College, Chennai” (2018).
20. Prescott PT. “Disorders of the adrenal cortex”. Medical Management of the Surgical Patient: A Textbook of Perioperative Medicine (2013): 358.
21. Hadji P., et al. “Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment”. Annals of Oncology12 (2011): 2546-2555.
22. Otomo‐Corgel J. “Osteoporosis and osteopenia: implications for periodontal and implant therapy”. Periodontology 20001 (2012): 111-139.
23. Guggenbuhl P. “Osteoporosis in males and females: Is there really a difference?” Joint Bone Spine6 (2009): 595-601.
24. Prevention O. “Diagnosis, and therapy”. NIH Consensus Statement1 (2000): 1-36.
25. Riggs BL and Melton LJ. “Osteoporosis: etiology, diagnosis, and management”. Lippincott Williams and Wilkins (1995).
26. Rao RD and Singrakhia MD. “Painful osteoporotic vertebral fracture: pathogenesis, evaluation, and roles of vertebroplasty and kyphoplasty in its management”. JBJS10 (2003): 2010-2022.
27. Siris ES., et al. “Bone mineral density thresholds for pharmacological intervention to prevent fractures”. Archives of Internal Medicine10 (2004): 1108-1112.
28. Kumar M., et al. “Anti-osteoporotic constituents from Indian medicinal plants”. Phytomedicine 13 (2010): 993-999.
29. Bateman ED., et al. “Global strategy for asthma management and prevention: GINA executive summary”. European Respiratory Journal 1 (2008): 143-178.
30. Health Udo and Services H. “Bioanalytical method validation, guidance for industry” (2001).

Citation

Citation: Swarnima Pandey and Sushant Kumar “An Overview on Osteoporosis and Herbal Plants Used for Treatment". Acta Scientific Pharmaceutical Sciences 6.3 (2022): 29-35.

Copyright

Copyright: © 2022 Swarnima Pandey and Sushant Kumar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.